Medical Marijuana Labeling and Lab Testing Standards

Dispensary shelves in legal states hold products with labels dense enough to rival a pharmaceutical insert — potency percentages, terpene profiles, batch numbers, contaminant limits, and harvest dates all competing for space on a one-inch sticker. Those labels exist because state regulators decided, product by product, that patients buying cannabis should know what they're actually getting. This page covers what those standards require, how testing laboratories produce the numbers behind them, where the system works well, and where it still has meaningful gaps.

Definition and scope

A medical marijuana labeling standard is a state-level regulatory requirement specifying what information must appear on cannabis product packaging before it reaches a patient. A lab testing standard is the companion requirement specifying how the product's chemical composition and safety profile must be verified before that label can be printed.

The two are inseparable. A label that says "22% THC" is only as reliable as the accredited laboratory that generated that figure. Every state with a legal medical marijuana program has promulgated rules for both, though the specific requirements differ considerably from California to Florida to Minnesota.

The federal scaffolding is thin. Because cannabis remains a Schedule I substance under the Controlled Substances Act, the FDA has not issued a comprehensive cannabis testing or labeling framework applicable to state markets (the FDA has approved specific cannabis-derived drugs — see FDA-approved cannabis-based medications — but those are a narrow category). In the absence of federal standards, the Association of Official Agricultural Chemists (AOAC International) and ASTM International's Committee D37 on Cannabis have published voluntary consensus standards that many state labs and regulators reference as technical benchmarks.

How it works

The testing pipeline follows a predictable sequence in most states:

1. Sampling — A licensed agent, often a state inspector or the laboratory itself, pulls a representative sample from a batch before it can be sold. California's Bureau of Cannabis Control, for example, specifies the minimum sample mass by product type.
2. Potency analysis — High-performance liquid chromatography (HPLC) is the dominant method for quantifying cannabinoids including THC, THCA, CBD, and CBDA. The conversion formula most states use to estimate "total THC" is: Total THC = THCA × 0.877 + Δ9-THC.
3. Contaminant screening — This covers pesticide residues (typically against EPA tolerance lists or state-specific action levels), heavy metals (lead, cadmium, arsenic, mercury), residual solvents from extraction processes, and microbial contamination including Aspergillus species, Salmonella, and E. coli.
4. Moisture and water activity — Relevant for flower products; high water activity creates conditions for mold growth during storage.
5. Certificate of Analysis (COA) — The laboratory issues a COA documenting every test result. This document is the authoritative record that the label data must match.

Once a batch passes all required tests, the dispensary or manufacturer prints labels that must typically include: the licensed producer's name, a batch or lot number, the harvest or manufacture date, the cannabinoid potency breakdown, net weight, serving size for edibles, required health warnings, and a symbol indicating it is a medical product. Understanding what those cannabinoid percentages mean in practice connects directly to cannabinoids, THC, and CBD explained.

Laboratory accreditation is a critical gate. Most states require cannabis testing labs to hold ISO/IEC 17025 accreditation — the international standard for testing and calibration laboratory competence — issued by an accreditation body such as A2LA (American Association for Laboratory Accreditation) or Perry Johnson Laboratory Accreditation (PJLA).

Common scenarios

Flower products carry the most straightforward labeling: potency, strain name, harvest date, and contaminant pass/fail. The challenge is that flower is a heterogeneous matrix — THC content varies across the same plant, which means testing results carry inherent variability. A 2019 study published in PLOS ONE found that THC potency reported on cannabis labels frequently exceeded measured potency, with some samples off by more than 23 percentage points.

Edibles and infused products require accurate dosing information because onset is delayed compared to inhalation (see medical marijuana delivery methods), making overconsumption more likely if label potency is wrong. Most states cap individual serving size at 10 mg THC and require total package THC to be disclosed.

Concentrates — including wax, shatter, and distillate — involve solvent-based or solventless extraction processes, making residual solvent testing particularly important. Colorado's Marijuana Enforcement Division, for example, maintains specific action levels for 67 solvents including butane, propane, and ethanol.

Topicals are tested for contaminants but potency standards vary; most states do not require child-resistant packaging for topicals because systemic absorption through intact skin is minimal.

Decision boundaries

The gaps and fault lines in this system are real and worth understanding clearly.

Interstate inconsistency is the largest structural problem. A product legal and labeled-compliant in Oregon cannot cross into Nevada without re-testing under Nevada's rules. There is no reciprocity framework, because federal law prohibits interstate cannabis commerce. Patients traveling between states encounter different rules entirely.

Lab shopping — the practice of submitting batches to multiple labs until obtaining a favorable result — has been documented in markets including Washington State and California. Some states responded by implementing mandatory random sampling by state agents rather than allowing producers to submit their own samples.

Terpene disclosure sits in a gray zone. Terpenes affect therapeutic character (see medical marijuana strains and types) and some states require quantified terpene profiles on COAs; others treat terpene provider as optional.

Action levels versus limits of detection create a meaningful distinction: a test that reports "ND" (not detected) for a pesticide only confirms the contaminant was below the instrument's detection threshold, not that zero residue exists. Patients with heightened sensitivity concerns — such as those undergoing cancer treatment (medical marijuana for cancer patients) — may want to understand this distinction when interpreting COAs.

The regulatory context for medical marijuana continues to evolve at the state level, and several states have tightened testing requirements following product recalls tied to undisclosed pesticide use. The underlying infrastructure — accredited labs, traceable sampling, standardized methods — is more mature than it was a decade ago, but it remains a patchwork rather than a system.